![UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy](https://mma.prnewswire.com/media/1336120/Vimpat.jpg?p=facebook)
UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy
![Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine - ScienceDirect Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1059131113000976-gr3.jpg)
Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine - ScienceDirect
![Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry | BioSpace Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry | BioSpace](https://mma.prnewswire.com/media/1245376/Vimpat.jpg)